medicina59巻3号

2022年03月発行

特集 成人が必要とするワクチン—生涯を通した予防接種の重要性 予防接種を必要とする成人 〈基礎疾患を持つ人〉

HIV感染症

著者： 菅沼明彦¹

所属機関： ¹新古賀病院総合診療科

ページ範囲：P.468 - P.474

Point
◎HIV感染者は，HIV感染症と同一の感染経路を有する他の感染症に罹患するリスクがある．
◎不活化ワクチンに絶対的な禁忌はないが，生ワクチンについては禁忌となるものと，一定の条件下で接種可能なものとがある．
◎CD4陽性リンパ球数，HIV-RNA量などの因子が，ワクチンの適応や効果に関連することを考慮する．

参考文献

1）Kunisaki KM, Janoff EN：Influenza in immunosuppressed populations；A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9：493-504, 2009

2）Centers for Disease Control and Prevention：Recommended adult immunization schedule by medical condition and other indications, United States, 2021.　https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html#table-conditions（2021年11月閲覧）

3）Finlayson TJ, et al：HIV risk, prevention, and testing behaviors among men who have sex with men—National HIV Behavioral Surveillance System, 21 U.S. cities, United States, 2008. MMWR Surveil Summ 60：1-34, 2011

4）Peters PJ, et al：HIV-infected hospitalized patients with 2009 pandemic influenza A（pH1N1）—United States, spring and summer 2009. Clin Infect Dis 52：S183-188, 2011

5）Yanagisawa N, et al：Reduced immune response to influenza A（H1N1）2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine 29：5694-5698, 2011

6）George VK, et al：HIV infection worsens age-associated defects in antibody responses to influenza vaccine. J Infect Dis 211：1959-1968, 2015

7）Yamanaka H, et al：Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 39：167-173, 2005

8）Madeddu G, et al：Pneumococcal pneumonia；Clinical features, diagnosis and management in HIV-infected and HIV noninfected patients. Curr Opin Plum Med 15：236-242, 2009

9）Marcus JL, et al：Invasive pneumococcal disease among HIV-infected and HIV-uninfected adults in a large integrated healthcare system. AIDS Patient Care STDS 30：463-470, 2016

10）Curran A, et al：Bacterial pneumonia in HIV-infected patients：use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med 9：609-615, 2008

11）Teshale EH, et al：Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 26：5830-5834, 2008

12）Centers for Disease Control and Prevention：Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions；Recommendations of the Advisory Committee on Immunization Practices（ACIP）. MMWR Morb Mortal Wkly Rep 61：816-819, 2012

13）河原隆二，他：＜速報＞2013年度の侵襲性肺炎球菌感染症の患者発生動向と成人患者由来の原因菌の血清型分布—成人における血清型置換（serotype replacement）について．IASR 35：179-181, 2014

14）Ishida T, et al：Outbreak of hepatitis A virus infection among HIV-1 seropositive men who had sex with men. Jpn J Infect Dis 52：131-132, 1999

15）Centers for Disease Control and Prevention：Hepatitis A vaccination of men who have sex with men—Atlanta, Georgia, 1996-1997. MMWR Morb Mortal Wkly Rep 47：708-711, 1998

16）清原知子，他：わが国におけるA型肝炎の血清疫学．IASR 31：286-287, 2010

17）国立感染症研究所 感染症疫学センター：2012年第1週から2018年第19週までの感染症発生動向調査におけるA型肝炎の報告状況．　https://www.niid.go.jp/niid/ja/id/1558-disease-based/a/hepatitis/hepatitis-a/idsc/idwr-sokuhou/8071-hepa-180531.html（2021年11月閲覧）

18）Ida S, et al：Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 34：379-385, 2002

19）Rimland D, Guest JL：Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 19：1702-1704, 2005

20）Crum-Cianflone NF, et al：Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 203：1815-1823, 2011

21）Lin KY, et al：Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients；A review. World J Gastroenterol 23：3589-3606, 2017

22）菅沼明彦：HIV関連梅毒の特徴．IASR 36：22-23, 2015

23）Fujisaki S, et al：Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. Clin Microbio 49：1017-1024, 2011

24）van den Berg R, et al：Non-responsiveness to hepatitis B vaccination in HIV seropositive patients；Possible causes and solutions. AIDS Rev 11：157-164, 2009

25）武内世生，他：HIV感染者に対するB型肝炎ワクチンの有用性．日エイズ会誌16：37-40, 2014

26）O'Bryan TA, et al：HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels. HIV Med 16：161-167, 2015

27）Kreuter A, Wieland U：Human papillomavirus-associated diseases in HIV-infected men who have sex with men. Curr Opin Infect Dis 22：109-111, 2009

28）Advisory Committee on Immunization Practices：Recommended adult immunization schedule；United States, 2012. Ann Intern Med 156：211-217, 2012

29）Wilkin T, et al：Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202：1246-1253, 2010

30）Cheng SH, et al：Multiple types of human papillomavirus infection and anal precancerous lesions in HIV-infected men in Taiwan；A cross-sectional study. BMJ Open 8：e019894, 2018

31）Hawkins KL, et al：Herpes zoster and herpes zoster vaccine rates among adults living with and without HIV in the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr 79：527-533, 2018

32）Oxman MN, et al：A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352：2271-2284, 2005

33）Benson CA, et al：Safety and immunogenicity of zoster vaccine live in human immunodeficiency virus-infected adults with CD4＋ cell counts ＞200 cells/mL virologically suppressed on antiretroviral therapy. Clin Infect Dis 67：1712-1719, 2018

34）Lal H, et al：Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372：2087-2096, 2015

35）Berkowitz EM, et al：Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults；A phase 1/2a randomized, placebo-controlled study. J Infect Dis 211：1279-1287, 2015

36）Del Amo J, et al：Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy；A cohort study. Ann Intern Med 173：536-541, 2020

37）Cooper TJ, et al：Coronavirus disease 2019（COVID-19）outcomes in HIV/AIDS patients；A systematic review. HIV Med 21：567-577, 2020

38）Guo W, et al：A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan, China. SSRN Electron J, 2020［preprint］

39）Liang M, et al：Prevalence and mortality due to COVID-19 in HIV co-infected population；A systematic review and meta-analysis. Infect Dis Ther 10：1267-1285, 2021